- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
GLP-1 Receptor Agonists Linked to Slightly Increased Risk of Smell and Taste Disturbances: JAMA

Israel: An analysis of electronic health record data found that adults with type 2 diabetes who used GLP-1 receptor agonists had a higher risk of developing smell and taste disturbances over two years compared with non-users. Reported smell disorders included anosmia (loss of smell) and parosmia (distorted smell), while taste disorders primarily involved parageusia (distorted taste). However, the absolute increase in risk was very small, indicating that these adverse effects remain uncommon.
- Patients using GLP-1 receptor agonists had a 48% higher risk of developing new smell or taste disturbances than matched controls (HR 1.48).
- GLP-1 receptor agonist use was associated with an 81% higher risk of smell disturbances (HR 1.81).
- The risk of taste disturbances was 52% higher among GLP-1 receptor agonist users compared with non-users (HR 1.52).
- The increased risk of smell and taste disturbances remained consistent throughout the follow-up period, from 3 months to 2 years after treatment initiation.
- Despite the higher relative risk, the absolute number of smell and taste disturbance cases was low, indicating that these adverse events remain uncommon.
- Smell and taste disturbances were identified using ICD diagnostic codes rather than standardized objective testing, raising the possibility of underreporting or misclassification of cases.
**Dr. Kartikeya Kohli** is a Senior Consultant in Internal Medicine at Max Super Speciality Hospital, Saket, New Delhi, with over 15 years of clinical experience. He specializes in Diabetes and Metabolic Medicine, Obesity Management, Hypertension, Cardiovascular Risk Reduction, Kidney Diseases, and Preventive Healthcare. He holds DNB in Medicine and MRCP (UK), with advanced training in Nephrology and postgraduate qualifications in Clinical Endocrinology & Diabetes, Advanced Diabetes Care, and Cardiology & ECG from the Royal College of Physicians. Dr. Kohli is actively involved in medical education and healthcare communication, having organized over 100 CME programmes and authored more than 200 medical articles and clinical updates. He has received several recognitions, including the IMA Distinguished Academician Award, Chikitsa Ratan Award, and Phoenix Award at AICON 2026.

